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Endocrine therapy has been widely used in treating estrogen receptor (ER)-positive breast cancer which accounts 
for nearly 75% of breast cancer. Though endocrine therapy has shown great potency, acquired resistance occurs. 
Fulvestrant, the first selective ER down-regulator (SERD), was confirmed to completely suppress ERα and 
notably efficient. However, it has been observed that some ER-positive breast cancer would eventually develop 
unresponsiveness and acquired resistance to it, resulting in poor outcome. Several mechanisms have been 
proposed to be involved in antiestrogen resistance, such as activated pathways and altered expression of 
microRNAs. Of note, it is postulated androgen receptor (AR) which is often observed in most primary and 
metastatic breast cancer, might be a crucial protein associated with the efficacy of Fulvestrant, due to its common 
co-expression and intricate crosstalk with ER. In this study, we demonstrate that treatment suppressing ER 
would shift tumors from ER dependence to AR dependence, resulting in resistance to Fulvestrant and tumor 
growth. A blockade of AR could increase the sensitivity to Fulvestrant, and dual inhibition of AR and ER would 
be more effective than either drug alone, which might provide an insight into choosing optimal therapy for 
patients with AR-expressing ER-positive breast cancer. Furthermore, activated AR could also upregulate its 
downstream factor SOX9 to promote cell migration and proliferation. 
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Currently, breast cancer is the one of the leading causes 
among all cancer-related deaths [1]. Despite of early diagnosis 
and comprehensive treatment, especially the development of 
endocrine therapy, the mortality of breast cancer has still 
remained relatively high [1]. Highly heterogeneous as breast 
cancer is, different subtypes have different biological 
behaviors and clinical prognosis. Among all the subtypes, 
estrogen receptor (ER)-positive breast cancer is the most 
common one [2, 3]. ER forms estradiol/ER complex with 
estradiol, mediating gene transcription via receptor dimeriza-
tion and nuclear translocation, further activating multiple 
pathways to promote cell growth [4, 5].  
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Endocrine therapy or antiestrogen therapy is the treatment 
that targets on ER. Current widely used antiestrogen agents 
include selective ER modulators (SERMs, e.g., Tamoxifen) 
which could interfere with estrogen signaling, aromatase 
inhibitors (AIs, e.g., Letrozole) that function as estrogen 
biosynthesis inhibitors, and selective ER downregulators 
(SERDs, e.g., Fulvestrant) which could degrade ER [6]. 
However, despite the potent anti-tumor activity, the resistance 
in ER-positive breast cancer to these agents is inevitable, 
eventually leading to tumor progression and metastasis. 
Whereas mechanisms regarding SERMs and AIs resistance 
have been widely studied including pathway activation and 
altered microRNA, what leads to Fulvestrant resistance is still 
waiting to be elucidated [6].  
Intriguingly, androgen receptor (AR) which is often 
observed in most primary and metastatic breast cancer, is 
considered a crucial protein associated with the efficacy of 
endocrine therapy due to its common co-expression with ER 
[7]. Cumulative studies have shown in ER-positive breast 
cancer patients, AR expression is not only a favorable 
prognostic factor in terms of tumor size, tumor grade, Ki-67 
levels and response to treatment, but also is associated with a 
better outcome [8-11]. However, on the contrary, there also 
exists evidence indicating higher level of AR might suggest a 
worse prognosis. A cohort study of 192 patients with ER-
positive breast cancer showed that a high AR/ER ratio of at 
least 2.0 predicted a higher risk of failure of tamoxifen [12]. It 
has also been found that AR overexpression could contribute 
to the development of hormonal therapy resistance via various 
mechanisms [12-14]. For example, overexpressed AR, by 
enhancing tamoxifen’s effect as an agonist, induced the ER-
downstream signaling pathways which subsequently drove 
cell growth and proliferation [13, 15]. Besides, independent of 
ER, Dihydrotestosterone (DHT), an AR agonist, was found to 
induce epithelial-mesenchymal transition (EMT) in MCF-7 
cells [16], which might precipitate resistance to hormonal 
therapy. Herein, we hypothesized that treatment suppressing 
ER turns tumors from ER dependence to AR dependence, 
resulting in resistance to antiestrogen agents and activation of 
AR pathway.   
Materials and Methods 
Cell Lines and Reagent 
Breast cancer cell line MCF-7 was purchased from the 
Chinese Academy of Science Committee Type Culture 
Collection Cell Bank (Shanghai, China) in 2018. Fulvestrant-
resistant (FulR) breast cancer cell line was purchased from 
AXOL Bioscience in 2018. MCF-7 cells were cultured in 
DMEM medium (Gibco, USA) with 10% fetal bovine serum 
(FBS; Gibco, USA) and 1% penicillin/streptomycin. FulR 
cells were cultured in phenol red-free DMEM/F12 medium 
(KeyGEN BioTECH, China) containing with 100 nM 
Fulvestrant, supplemented with 1% fetal bovine serum (FBS; 
Gibco, USA) and 1% penicillin/streptomycin, with additional 
2.5 mM GlutaMAXTM (Gibco, USA) and 6 ng/mL insulin. 
Cells were then incubated in a humidified atmosphere with 5% 
CO2 at 37℃. Fulvestrant, Bicalutamide and DHT were 
purchased from MedChem Express. 
Microarray Analysis  
Samples for microarray analysis were MCF-7 and FulR 
cells. Total RNA was extracted from MCF-7 and FulR cells 
using TRIzol reagent (Invitrogen, USA) according to the 
manufacturer’s protocol. RNA was amplified to produce 
double-stranded cDNA which was subsequently purified and 
transcribed to cRNA using T7 Enzyme Mix. Then, CbcScript 
II reverse transcriptase and Klenow Fragment enzyme was 
used to produce cDNA and labeling. 
The labeled and fluorescent cDNA was then hybridized in 
a Agilent hybridization oven overnight. Array was then 
scanned and acquired array images were analyzed by Agilent 
Feature Extraction software V11.0.1.1. Normalization and 
quality control were performed using the Agilent GeneSpring 
GX software version 12.1 (Agilent Technologies). mRNAs 
with fold-change ≥ 2.0 and a P-value ≤ 0.05 were considered 
significantly different. Benjamini-Hochberg was used to 
correct for multiple statistical tests. 
Lentivirus Transfection and Transient Transfection 
To investigate the role of SOX9, we transfected MCF-7 
with recombinant lentivirus of SOX9 from Applied Biological 
Materials (ABM; Zhenjiang, China) as well as an empty 
vector control. Cells were harvested after 72 hours of 
transfection for further study. To select the stable transfected 
SOX9-overexpressed cells, Puromycin was used and the 
concentration for selection was 2 ug/mL. 
The shRNA sequences were synthesized by GenePharma 
(Shanghai, China) as followed: shSOX9-1, CCACCTTCAC-
CTACATGAA; shSOX9-2, CAGCGAACGCACATCAAGA; 
shNC, AGTGCACGTGCATGTCCTA. Cells were transfect-
ed with lentiviral vectors following standard procedures from 
manufacturer. 
Cell Survival Assay 
Cell viability was measured using Cell Counting Kit-8 
(CCK-8) (MedChem Express, China). Briefly, cells were 
seeded into a 96-well plate at a density of 5×103 cells/well with 
6 repeats for each condition. After 24 hours, the cells were 
treated with Fulvestrant, Bicalutamide, DHT or the 
combination of Fulvestrant and Bicalutamide for another 48 
or 72 hours. Then, the supernatants were removed and 100 μl 
medium with 10 μl CCK-8 was added into each well of the 
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plate and incubated at 37℃. After 2 hours, the absorbance 
value (OD) of each well was measured at 450 nm using an 
ELX-800 spectrometer reader (Bio-Tek Instruments, 
Winooski, USA). 
Cell Apoptosis Assay 
Cells transfected with SOX9 and/or treated with medication 
were incubated for 48 or 72 hours, then harvested by 
trypsinization (no EDTA) and washed three times with 
phosphate-buffered saline (PBS). For apoptosis analysis, the 
cells were resuspended in 500 μl of 1 × binding buffer and 
stained with 5 μl of Annexin V and 5 μl of PI for 15 minutes 
at room temperature in the dark. Assays were tested in 
triplicate. 
Wound Healing Assay 
Cells were seeded in six-well plates and incubated to 
generate confluent cultures. Using 200 μl sterile pipette tips, 
wounds were scratched in the cell monolayer and rinsed with 
PBS. Subsequently, the cells were cultured in serum-free 
medium for 48 hours. The migration of the cells was 
photographed at time 0 and 24 hours. 
Quantitative Real-Time PCR 
Total RNA was isolated from cells using TRIzol reagent 
(Invitrogen, USA) according to the manufacturer’s protocol. 
Then, cDNA was synthesized in a reaction mix containing 2 
mg RNA and PrimeScript RT reagent Kit with gDNA Eraser 
(Takara, Japan). Quantitative RT-PCR was implemented with 
Step One (TM) sequence detection system (Applied 
Biosystems Inc, Milan, Italy) using validated primers and 
SYBR Premix Ex Taq II (Takara, Japan). The cycle number at 
threshold (Ct) was used to quantify the transcript levels of 
genes of interest. Primer sequences were listed below: β-Actin, 
forward 5’-CTGGAACGGTGAAGGTGACA-3’ and reverse 
5’-AAGGGACTTCCTGTAACAACGCA-3’; ESR, 5’-
TGCCTGGCTAGAGATCCTGA-3’ and reverse 5’-
CTCCACCATGCCCTCTACAC-3’; AR, forward 5’-
GCAACTCCTTCAGCAACA-GC-3’ and reverse 5’-
GACACCGACACTGCCTTACA-3’; SOX9, forward 5’-
GACTTCTGAA-CGAGAGCGAGA-3’ and reverse 5’-
CCGTTCTTCACCGACTTCCTC-3’; GREB1, forward 5’-
ATCAGCTGCTCGGACTTGCTG-3’ and reverse 5’-
TGAGCTCCGGTCCTGACAGATG-3’; PGR, forward 5’-
GGCGAGAGGCAACTTCTTTC-3’ and reverse 5’-
CATCTGCCCACTG-ACGTGTT-3’; TFF1, forward 5’- 
GTGTCACGCCCTCCCAGT-3’ and reverse 5’- 
GGACCCC-ACGAACGGTG-3’; FKBP5, forward 5’-
CATGCAGGCGGTGATTCAGTA-3’ and reverse 5’-
GTTCAGAAAGGCAGCAAGGAG-3’. Each sample was 
tested in triplicate and normalized for β-Actin expression. 
Western Blotting 
The whole protein was extracted by RIPA buffer 
supplemented with protease and phosphatase inhibitors. 20 μg 
cell lysates were loaded per lane and resolved by sodium 
dodecylsulfate-polyacrylamide (SDS-PAGE) electrophoresis 
and blotted onto polyvinylidene fluoride (PVDF) membranes. 
Following 2-hour blockade with 5% skim milk in tris-buffered 
saline/0.1% tween-20, the membranes were incubated with the 
primary antibodies overnight at 4℃ and with a horseradish 
peroxidase-conjugated secondary antibody (1:10000) for 2 
hours the next day. Antibodies for detecting SOX9 (#82630) 
and β-Actin (#4967) were from Cell Signaling Technology. 
Antibodies for detecting ER (ab32063) and AR (ab74272) 
were from Abcam. Results from at least two separate 
experiments were analyzed. 
Immunofluorescence  
MCF-7 and FulR cells were plated on eight-well chamber 
slides (Lab-Tek Products, Illinois, USA) and were stained 
according to immunofluorescence as described [17]. 
Immunofluorescence images were obtained using an Olympus. 
Statistical Analysis  
All the in vitro experiments were performed in triplicate. 
Statistical tests were performed using GraphPad Prism version 
7 (GraphPad Prism, San Diego). Data were analyzed using 
either F-test or Student t-tests. P < 0.05 was considered 
statistically significant. 
Results 
Fulvestrant-resistant ER-positive breast cancer cell growth 
was associated with AR expression 
To establish Fulvestrant-resistant (FulR) ER-positive 
cell line model, we cultured MCF-7 cells in long-term 
estrogen-deprived (LTED) condition with Fulvestrant. 
Dose-response experiments showed that a significant 4.7-
fold increase in the Fulvestrant IC50 in FulR cells compared 
with MCF-7 cells (MCF-7 Fulvestrant IC50 = 5.73 × 10-5 M, 
FulR Fulvestrant IC50 = 27.02 × 10-5 M, P = 0.0486) (Fig. 
1a). 
Since ER is the key driver of tumor development in ER-
positive breast cancer [4], we first assessed its role in cell 
growth in FulR cell line model. The results showed that in 
FulR cells, the expression of ER was lower than those in 
MCF-7 cells. Correspondingly, the representative downs-
tream proteins of ER pathway such as GREB1, PGR and 
TFF1, were substantially less activated (Fig. 1b), indicating 
FulR cells proliferation might not be dependent on ER.  
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Figure 1. Fulvestrant-resistant ER-positive breast cancer cell growth depends on AR. (a) Dose-response curves for Fulvestrant treatment in MCF-
7 and FulR cells. MCF-7 Fulvestrant IC50 = 5.73 × 10 -5 M and FulR Fulvestrant IC50 = 27.02 × 10 -5 M, P = 0.0486. (b) PCR and western blotting 
showed a decreased ER and ER downstream proteins GREB1, PGR and TFF1 in FulR cells compared with MCF-7 cells. (c) PCR and western blotting 
showed an increased AR and AR downstream protein FKBP5 in FulR cells compared with MCF-7 cells. (d) Immunofluorescence of AR in MCF-7 and 
FulR cells. (e) Western blotting confirmed the decreased or increased expression of AR by 20 μM Bicalutamide or 100 nM DHT. Cell viability detected 
by CCK-8 on days 1, 3, and 5 in MCF-7 and FulR cells treated with either 20 μM Bicalutamide or 100 nM DHT, compared to untreated cells. 
 
 
Based on the evidence shown in previous studies that AR 
could confer antiestrogen therapy resistance [12, 13], as 
well as its intricate interaction with ER [18], we 
subsequently determined the impact of AR on cell growth 
and found AR was highly expressed in FulR cells, with an 
activated downstream pathway, shown by upregulated 
FKBP5 which is an typical AR-binding element (Fig. 1c). 
As is known, nuclear AR is canonical in terms of cell 
proliferation promotion [19]. Therefore, immunofluore-
scence was performed to detect the nuclear translocation of 
AR. Compared with MCF-7 cells, in which scarce nuclear 
AR was found, FulR cells had a higher expression of both 
cytoplasmic and nuclear AR (Fig. 1d), which was 
consistent to aforementioned upregulated AR downstream 
pathway.   
To better understand whether proliferation of FulR cells 
is related with AR, Bicalutamide (an AR antagonist) and 
DHT (an AR agonist) were used to treat both MCF-7 and 
FulR cells. Identical to what has been discussed in 
preclinical studies [11], different roles of AR were found in 
the two cell lines. In Fulvestrant-sensitive MCF-7 cell line, 
activation of AR contributed to growth inhibition, while in 
FulR cells, activated AR led to cell proliferation (Fig.1e). 
Thus, we verify that cell proliferation in FulR cells might 
rely on the activation of AR instead of ER. As a consequence, 
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Figure 2.  Inhibiting AR restores cell sensitivity to Fulvestrant. (a) Dose-response curves of FulR cells treated by 1 × 10 -8 - 1 × 10 
-4 M Fulvestrant with or without a constant dose of Bicalutamide for 48 h. (b and c) Dose matrix and CI vs. Fa plot (Combination index 
vs. Fraction affected) of 1 × 10 -7 - 1 × 10 -3 M Fulvestrant in combination with 2 - 64 μM Bicalutamide for 48 h. The CI values were 
calculated by CompuSyn Software, with a value below 1 considered synergistic. (d) Apoptosis analysis of untreated FulR cells and FulR 
cells after treatment of 100 nM Fulvestrant for 72 h or combined 20 μM Bicalutamide with 100 nM Fulvestrant for 48 h. 
 
resistance to Fulvestrant develops.  
Inhibition of AR re-sensitized Fulvestrant-resistant ER-
positive breast cancer cells 
Since we have demonstrated a shift to AR dependence 
could reduce the sensitivity to Fulvestrant in ER-positive 
breast cancer, we next hypothesized inhibition of AR could 
reverse Fulvestrant resistance and restore the sensitivity in 
cells. Via the dose-response experiments, we found that 
blocking AR by Bicalutamide significantly increased 
responsiveness to Fulvestrant in a dose-dependent manner 
in ER-positive breast cancer cells (Fig. 2a). The dose matrix 
showed that combination of Bicalutamide with Fulvestrant 
was more effective than either agent alone, showing a 
synergistic interaction (Fig. 2b and 2c). To further 
characterize the effects of the combination, we performed 
apoptosis assay in FulR cells treated with Bicalutamide, 
Fulvestrant or the combination. Consistent with our 
previous results, addition of AR inhibitor to Fulvestrant 
triggered higher cell apoptosis compared with either 
treatment alone in FulR cells (Fig. 2d). Taken together, 
inhibition of AR could help Fulvestrant-resistant cells 
regain sensitivity to Fulvestrant in a dose-dependent 
manner.  
SOX9 might be involved in AR-related EMT.  
Furthermore, we characterized FulR cells and observed 
that the morphology of FulR cells. Different from the 
morphology of Fulvestrant-sensitive MCF-7 cells, FulR 
cells exhibited a mesenchymal-like appearance (Fig. 3a). 
Western blotting showed decreased expressions of cell 
adhesion molecules and increased expressions of 
mesenchyme-related proteins (Fig. 3a), suggesting EMT 
was promoted in FulR cells. In line with the morphological 
and molecular changes, the enrichment of Gene Ontology 
(GO) terms derived from RNA microarray also revealed 
substantial changes of cell adhesion-related functions (Fig. 
3b).  
Based on prior literature that showed AR could promote  
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Figure 3. RNA microarray and String prediction results indicate SOX9 might be involved in AR-related EMT promotion. (a) Brightfield 
microscopy pictures of 2D culture of MCF-7 and FulR cells. Magnification, 10×. Western blotting of EMT-associated proteins. (b) Top 30 significantly 
enriched GO terms related with biological process in FulR cells, MCF-7 as control. (c) Top 10 up- and down-regulated proteins associated with cell 
adhesion regulation. (d) Prediction of the 20 proteins that might interact with AR using String prediction algorithm (http://string-db.org). 
 
 
EMT [16], we next investigated the underlying mechanisms 
of AR in EMT and selected top ten up- and down-regulated 
proteins involved in regulation of cell adhesion (Fig. 3c). 
Using the String prediction algorithm (http://string-db.org), 
we found SOX9, which was upregulated by more than 6-
fold change, was predicted to have an interaction with AR 
(Fig. 3d).  
SOX9, upregulated by AR, promotes EMT and cell 
proliferation  
Previous studies have proved that AR could regulate 
SOX9 in prostate cancer [20]. To further investigate the 
relation between AR and SOX9 in ER-positive breast 
cancer, first we validated the results from RNA microarray 
and confirmed increased mRNA and protein expressions of 
SOX9 in FulR cells (Fig. 4a). Then, we overexpressed 
SOX9 in Fulvestrant-sensitive MCF-7 cells and found cell 
migration in SOX9-overexpressed MCF-7 was increased 
(Fig. 4b), consistent with the previous findings that AR 
could promote EMT [16]. 
To determine if SOX9 is also regulated by AR in breast 
cancer, we treated MCF-7 cells with Bicalutamide or DHT. 
Western blotting showed a decreased SOX9 expression in 
Bicalutamide-treated FulR cells and an increased SOX9 
expression in DHT-treated FulR cells (Fig. 4c). Then, by 
knocking down SOX9 in FulR cells, we found that 
silencing SOX9 did not have an impact on AR expression, 
showing that AR expression might not depend on SOX9  
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Figure 4. AR upregulates SOX9 to facilitate EMT and cell proliferation. (a) PCR and western blotting of SOX9 in MCF-7 and FulR cells. (b) 
Western blotting and cell migration in MCF-7 cells transfected with SOX9 or an EV control. (c) Western blotting of AR and SOX9 in FulR cells after 
treatment with 20 μM Bicalutamide or 100 nM DHT for 48 h, compared to untreated FulR cells. PCR and western blotting of AR and SOX9 in FulR 
cells with SOX9 silencing using two different shRNAs or an shRNA control (shNC). (d) Cell viability detected by CCK-8 on days 1, 3, and 5 in FulR 
cells after silencing SOX9 with two different shRNAs or an shRNA control (shNC). Cell viability detected by CCK-8 on days 1, 3, and 5 in MCF-7 
cells overexpressed with SOX9 or an EV control.  
 
 
(Fig. 4c). Shortly, SOX9 might function as one of the 
important downstream elements of AR pathway in ER-
positive breast cancer.  
As a transcription factor, SOX9 has been demonstrated 
to regulate tumor growth [21]. In Figure 4d, we assessed 
whether proliferation of FulR cells is contingent on SOX9. 
As a result, knockdown of SOX9 in FulR cells, compared 
with control, markedly inhibited cell growth, while 
overexpression of SOX9 largely promoted cell growth in 
MCF-7 cells. 
Discussion  
Potent as endocrine therapy is in treating ER-positive 
breast cancer, however, the resistance to anti-estrogen 
therapeutics has gradually developed. To further improve 
the life span and quality for those patients, it is urgent to 
clarify mechanisms underlying such resistance so as to 
identify and develop new diagnostic methods and 
therapeutics.  
Androgens are important for both normal breast cells and 
breast cancer cells, and its receptor AR is critical for breast 
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cancer development as well [22]. Besides, due to the 
complex interaction between AR and ER, the implication 
of AR in breast cancer has been increasingly recognized. 
Evidence has shown that in primary breast cancer, high 
expression of AR is associated with low tumor burden and 
a favorable tumor cell differentiation [9]. Studies 
evaluating AR in patients with early breast cancer also 
suggested that AR expression is correlated with better 
outcome in terms of both overall survival (OS) and disease-
free survival (DFS) [8, 10]. However, controversy about the 
role of AR in ER-positive breast cancer exists and no 
consensus has been reached. Data based on ER-positive 
primary invasive breast cancer patients showed that more 
aggressive biological features and worse prognosis were 
observed in patients with a AR/ER ratio ≥ 2 [14]. 
Additionally, highly expressed AR may also have an 
impact on the sensitivity to tamoxifen in ER-positive breast 
cancer [12, 13, 15]. In our study, we identified that blocking 
ER in the long term using Fulvestrant would potentially 
induce breast cancer cell adaption from ER dependence to 
AR dependence. Such adaption renders it possible for ER-
positive breast cancer cells to escape from inhibition by ER 
blockade and sustain growth.  
Considering the critical role of AR in Fulvestrant 
resistance development, we used AR inhibitors 
Bicalutamide alone to treat FulR cells but found it could 
only moderately inhibit cell viability. However, the 
suppression effect by Bicalutamide was substantially 
improved when it was combined with Fulvestrant. 
Similarly, Bicalutamide also increased cell sensitivity to 
Fulvestrant reciprocally. We speculated that blocking AR 
might shift cells from ER independence to ER dependence, 
subsequently activating ER signaling and increasing 
sensitivity to Fulvestrant in FulR cells. Thus, simultaneous 
blockade of AR and ER is more effective than either drug 
alone.  
We also found that the increased AR could induce EMT 
and enhance migration in AR-dependent and Fulvestrant-
resistant ER-positive breast cancer cells, which is 
consistent with previous study [16]. Further experiments 
based on prior microarray data found that SOX9 could 
function as an AR downstream element to promote 
migration and proliferation in breast cancer cells. 
Intriguingly, another study demonstrated that in ER-
dependent and Tamoxifen-resistant ER-positive breast 
cancer cells, SOX9 could be regulated by ER and then 
induce Tamoxifen resistance [21]. In consideration of the 
involvement of SOX9 in both AR and ER pathways, and 
the association between AR and ER, more in-depth 
research about the role of SOX9 in endocrine therapy 
resistance is anticipated.  
In conclusion, our study demonstrated that AR might be 
closely related with obtained resistance to Fulvestrant in 
ER-positive breast cancer cells. By inhibiting AR, 
sensitivity to Fulvestrant could be regained. Besides, AR 
could upregulate SOX9 and further promote cell 
proliferation and migration in AR-dependent ER-positive 
breast cancer cells.  
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